Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7897148B2 · kind B2 · utility
0Cited by
26References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 7, 2007 |
| Grant date | Mar 1, 2011 |
| Priority date | — |
| Expiry date | Dec 7, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.